dhfr-1 Antibody

What is DHFR and why is it an important target for antibody-based research?

DHFR (dihydrofolate reductase) is a crucial enzyme that catalyzes the NADPH-dependent reduction of dihydrofolic acid to tetrahydrofolic acid, which serves as a methyl group shuttle required for de novo synthesis of purines, thymidylic acid, and specific amino acids . The enzyme plays a fundamental role in one-carbon transfer chemistry essential for DNA synthesis and cellular proliferation. DHFR antibodies enable researchers to study this enzyme's expression, localization, and function in various biological contexts, including cancer research, drug development, and gene amplification systems. DHFR deficiency has been associated with megaloblastic anemia, and DHFR knockdown has been linked to the anticancer activity of certain compounds such as 2-hydroxyoleic acid . Additionally, polymorphisms in the DHFR gene have been connected to variations in serum and red blood cell folate concentrations in women .

What types of DHFR antibodies are available for research, and how do they differ?

Research-grade DHFR antibodies are available in multiple formats, each with distinct characteristics suitable for different experimental applications:

Polyclonal antibodies like those derived from rabbit immunization with DHFR fusion proteins recognize multiple epitopes on the target protein, offering enhanced sensitivity for detection of low abundance targets . Monoclonal antibodies, such as those derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human DHFR, provide consistent performance across experiments with high specificity for particular epitopes . Some DHFR antibodies target specific amino acid regions (e.g., AA 1-50, AA 2-187, or AA 135-164) of the protein, which can be advantageous for studying particular domains or functional regions .

How is antibody specificity verified for DHFR across different species?

Validation of DHFR antibodies for cross-reactivity across species involves multiple methodological approaches:

The specificity of DHFR antibodies is verified through rigorous testing using multiple techniques across different species samples. Western blot analyses confirm target binding at the expected molecular weight (21 kDa for DHFR) . Positive reactivity in Western blots has been documented in samples from diverse sources including HEK-293 cells, HeLa cells, Jurkat cells, K-562 cells, Raji cells, mouse kidney tissue, mouse liver tissue, and rat kidney tissue . Immunoprecipitation assays further validate antibody specificity by confirming the ability to pull down the target protein from complex lysates, as demonstrated in Raji cells .

Immunohistochemistry testing on human liver cancer tissue and human breast cancer tissue provides evidence of specificity in tissue contexts, with optimization protocols involving antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0 . Immunofluorescence studies in cell lines like HeLa cells confirm proper subcellular localization patterns consistent with known DHFR distribution . Some antibodies have additional validation through knockout/knockdown studies, which represent the gold standard for specificity confirmation .

The expected species reactivity profile for many DHFR antibodies includes human, mouse, and rat, with some antibodies showing additional predicted reactivity to bovine and pig samples .

What are the optimal conditions for using DHFR antibodies in Western blot analyses?

Optimizing Western blot protocols for DHFR antibodies requires careful consideration of multiple parameters to achieve reliable, reproducible results:

The recommended dilution range for DHFR antibodies in Western blot applications typically falls between 1:1000 and 1:6000, although this must be empirically determined for each experimental system . DHFR's calculated molecular weight is 21 kDa, and the observed molecular weight in SDS-PAGE also corresponds to 21 kDa, providing a clear target band for identification .

For sample preparation, researchers should extract total protein from cells or tissues using standard lysis buffers containing protease inhibitors. Approximately 20-30 μg of total protein per lane is generally sufficient for detection of DHFR in most cell types, though this may vary depending on expression levels. Sample denaturation should be performed at 95°C for 5 minutes in loading buffer containing SDS and a reducing agent.

After protein transfer to nitrocellulose or PVDF membranes, blocking should be performed using 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature. Primary antibody incubation is recommended overnight at 4°C with gentle rocking in blocking solution. Following thorough washing with TBST (at least 3×10 minutes), HRP-conjugated secondary antibody should be applied at appropriate dilution (typically 1:5000-1:10000) for 1 hour at room temperature. After additional washing steps, detection can be performed using enhanced chemiluminescence reagents.

Positive controls such as HEK-293 cells, HeLa cells, Jurkat cells, K-562 cells, or Raji cells provide reliable reference samples for validation . For tissues, mouse kidney, mouse liver, and rat kidney have been confirmed to express detectable levels of DHFR .

How should DHFR antibodies be used in immunohistochemistry for optimal staining?

Successful immunohistochemical detection of DHFR requires careful optimization of several parameters:

For DHFR immunohistochemistry (IHC), the recommended antibody dilution range is 1:50-1:500, though this should be optimized for specific tissue types and fixation methods . Antigen retrieval is critical for unmasking epitopes in formalin-fixed, paraffin-embedded tissues. For DHFR antibodies, two effective antigen retrieval methods have been identified: (1) TE buffer at pH 9.0 (primary recommendation) or (2) citrate buffer at pH 6.0 as an alternative .

The protocol should include deparaffinization and rehydration of tissue sections, followed by the appropriate antigen retrieval method. Endogenous peroxidase blocking (3% H₂O₂ in methanol for 15 minutes) and protein blocking (5% normal serum in PBS for 1 hour) should precede primary antibody incubation. DHFR antibody should be applied overnight at 4°C in a humidified chamber.

After washing steps with PBS (3×5 minutes), an appropriate detection system (such as biotin-streptavidin-HRP or polymer-based systems) should be applied according to manufacturer's instructions. DAB (3,3'-diaminobenzidine) is commonly used as the chromogen, followed by hematoxylin counterstaining.

Human liver cancer tissue and breast cancer tissue have been validated as positive controls for DHFR antibody staining . Negative controls should include omission of primary antibody and, ideally, tissues from DHFR-knockout models when available.

What considerations are important for immunofluorescence applications with DHFR antibodies?

Immunofluorescence (IF) and immunocytochemistry (ICC) with DHFR antibodies require specific technical considerations:

For IF/ICC applications, the recommended dilution range for DHFR antibodies is 1:20-1:200, significantly more concentrated than for Western blot applications . Cell fixation is typically performed using 4% paraformaldehyde in PBS for 15 minutes at room temperature, followed by permeabilization with 0.1-0.3% Triton X-100 in PBS for 10 minutes.

After blocking with 5% normal serum in PBS containing 0.1% Triton X-100 and 1% BSA for 1 hour, primary antibody incubation should be conducted overnight at 4°C in blocking solution. Following washing steps (3×5 minutes with PBS), fluorophore-conjugated secondary antibodies should be applied at appropriate dilutions (typically 1:500-1:1000) for 1 hour at room temperature in the dark.

Nuclear counterstaining can be achieved using DAPI (1 μg/mL) for 5 minutes. After final washing steps, mounting should be performed using an anti-fade mounting medium to preserve fluorescence signal.

HeLa cells have been specifically validated for positive DHFR staining in IF/ICC applications . DHFR typically displays a predominantly cytoplasmic localization pattern, though some nuclear presence may also be observed depending on cell type and physiological state.

What are the proper storage and handling conditions to maintain DHFR antibody stability?

Maintaining antibody functionality requires strict adherence to storage guidelines:

DHFR antibodies are typically supplied in liquid form with specific buffer compositions for stability. Common storage buffers include PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . The glycerol acts as a cryoprotectant to prevent freezing damage, while sodium azide inhibits microbial growth.

For long-term storage, antibodies should be kept at -20°C, where they typically remain stable for at least one year after shipment . For periods up to one month, storage at 4°C is acceptable . It's crucial to avoid repeated freeze-thaw cycles, which can lead to protein denaturation and reduced antibody activity.

Certain antibody preparations may contain 0.1% BSA as a stabilizer in smaller volume formats (e.g., 20 μL sizes) , which helps maintain antibody functionality by preventing adhesion to container surfaces and providing colloid protection.

How can DHFR antibodies be utilized in DHFR/MTX-mediated gene amplification systems?

DHFR antibodies play a critical role in monitoring and validating DHFR-mediated gene amplification systems:

DHFR/methotrexate (MTX)-mediated gene amplification is a sophisticated system used to establish cell lines with enhanced production of recombinant proteins, particularly monoclonal antibodies. This system functions by linking a gene of interest (such as a monoclonal antibody gene) with the dhfr gene in an expression vector, which is then transfected into dhfr-deficient host cells .

DHFR antibodies are essential for monitoring the expression levels of DHFR in these systems, providing critical information about gene amplification efficiency. When cells are subjected to increasing concentrations of MTX (e.g., 1, 10, and 100 nM), selective pressure drives the amplification of both the dhfr gene and the linked gene of interest, resulting in increased productivity .

Western blot analysis using DHFR antibodies enables researchers to quantify DHFR protein levels across different MTX concentration steps, confirming successful gene amplification. Immunofluorescence applications can be used to visualize the distribution pattern of amplified gene loci within nuclei, which often appear as characteristic nuclear spots.

In HEK293 cell lines, DHFR antibodies have been instrumental in validating DHFR/MTX-mediated gene amplification systems. Research has demonstrated that dhfr-deficient HEK293 cells (generated by knocking out dhfr and dhfrl1 in HEK293E cells) can be effectively used with this amplification system to establish high-producing cell lines for monoclonal antibody production .

What approaches can resolve conflicting results when using different DHFR antibodies?

Resolving discrepancies between different DHFR antibodies requires a systematic troubleshooting approach:

When researchers encounter conflicting results using different DHFR antibodies, several methodological steps can help resolve these discrepancies. First, it's essential to compare the epitope recognition regions of each antibody. Different antibodies may target distinct regions of the DHFR protein (e.g., AA 1-50 versus AA 135-164) , potentially leading to different binding patterns, especially if post-translational modifications or protein interactions affect epitope accessibility.

Validation using multiple detection techniques provides more robust evidence of specificity. If an antibody yields unexpected results in one application (e.g., Western blot), confirming with orthogonal methods such as immunoprecipitation followed by mass spectrometry can help establish true specificity.

Knockout/knockdown validation represents the gold standard for antibody specificity confirmation. Comparing antibody reactivity in wild-type versus DHFR-knockout or DHFR-knockdown samples can definitively identify non-specific binding. Several DHFR antibodies have been validated using KD/KO approaches, with references to publications documenting these validations .

When working with samples from different species, it's critical to verify that the antibody has been validated for cross-reactivity with each specific species of interest. Some DHFR antibodies show reactivity with human, mouse, and rat samples, while others may have more limited species reactivity .

Technical considerations such as different blocking agents, incubation times, or detection methods can also contribute to discrepancies. Systematic optimization of these parameters may be necessary when comparing different antibodies.

What considerations are important when using DHFR antibodies in cancer research applications?

DHFR antibodies offer valuable tools for cancer research with specific methodological considerations:

DHFR is particularly relevant in cancer research due to its essential role in DNA synthesis and cellular proliferation, processes that are often dysregulated in cancer cells. Additionally, DHFR is the target of antifolate chemotherapeutic agents such as methotrexate, making it an important subject for cancer treatment studies.

When using DHFR antibodies in cancer research, tissue-specific optimization is essential. DHFR antibodies have been specifically validated for immunohistochemical detection in human liver cancer tissue and human breast cancer tissue . For these applications, antigen retrieval methods must be carefully selected, with TE buffer at pH 9.0 recommended as the primary method and citrate buffer at pH 6.0 as an alternative .

Comparative analysis of DHFR expression levels between normal and cancerous tissues can provide insights into potential dysregulation. Western blot protocols may need adjustment when comparing tissues with vastly different DHFR expression levels to avoid saturation in high-expressing samples while maintaining detection sensitivity for low-expressing samples.

Co-localization studies combining DHFR antibodies with markers of proliferation (such as Ki-67) or cell cycle regulators can provide contextual information about DHFR's role in cancer cell biology. Multi-color immunofluorescence approaches are particularly valuable for such applications.

When studying the effects of antifolate drugs on cancer cells, DHFR antibodies can be used to monitor changes in DHFR expression levels, which may indicate compensatory upregulation in response to treatment or selection of resistant cell populations.

How can DHFR antibodies be employed in studying drug resistance mechanisms?

DHFR antibodies provide crucial insights into mechanisms of resistance to antifolate drugs:

Antifolate resistance in cancer and other diseases often involves alterations in DHFR expression, structure, or regulation. DHFR antibodies facilitate investigation of these resistance mechanisms through multiple experimental approaches.

Quantitative Western blot analysis using DHFR antibodies enables researchers to compare DHFR protein levels between drug-sensitive and drug-resistant cell lines. This can reveal whether resistance correlates with DHFR overexpression, which is a common mechanism of acquired resistance to antifolate drugs. The recommended dilution range of 1:1000-1:6000 for Western blot applications allows for sensitive detection of changes in DHFR expression levels .

Immunofluorescence microscopy with DHFR antibodies can reveal changes in subcellular localization or distribution patterns that may contribute to drug resistance. For instance, altered nuclear-cytoplasmic distribution of DHFR might affect drug accessibility to the target enzyme. The suggested dilution range of 1:20-1:200 for IF/ICC applications provides appropriate sensitivity for such studies .

Immunoprecipitation using DHFR antibodies (recommended at 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate) followed by mass spectrometry can identify potential binding partners or post-translational modifications that might contribute to drug resistance mechanisms.

For clinical samples, immunohistochemistry with DHFR antibodies (dilution range 1:50-1:500) can assess whether DHFR expression levels correlate with treatment response or resistance in patient cohorts. This approach can help identify biomarkers for personalized treatment strategies.

What strategies can address weak or absent signals when using DHFR antibodies?

When encountering weak or absent signals with DHFR antibodies, a systematic troubleshooting approach is essential:

First, verify that your experimental system expresses detectable levels of DHFR by including positive control samples with known DHFR expression. Validated positive controls for Western blot include HEK-293 cells, HeLa cells, Jurkat cells, K-562 cells, Raji cells, mouse kidney tissue, mouse liver tissue, and rat kidney tissue .

Optimize antibody concentration by testing a range of dilutions. While the recommended ranges are 1:1000-1:6000 for Western blot, 1:50-1:500 for IHC, and 1:20-1:200 for IF/ICC , your specific experimental conditions may require adjustments outside these ranges.

For tissue samples in IHC or IF applications, insufficient antigen retrieval is a common cause of weak signals. Experiment with different antigen retrieval methods, comparing the recommended TE buffer at pH 9.0 with the alternative citrate buffer at pH 6.0 . Extend retrieval times or adjust temperatures if necessary.

Signal enhancement strategies can help overcome weak signals. These include: (1) Using signal amplification systems such as biotin-streptavidin complexes or tyramide signal amplification for IHC/IF applications, (2) Extending primary antibody incubation time from overnight to 48-72 hours at 4°C with gentle agitation, (3) Employing more sensitive detection reagents, such as enhanced chemiluminescence substrates with higher sensitivity for Western blot applications.

For Western blots specifically, ensure efficient protein transfer by validating transfer efficiency with reversible staining methods such as Ponceau S. DHFR's relatively small size (21 kDa) means it transfers relatively quickly, so standard transfer conditions should be sufficient.

How can background issues be resolved when working with DHFR antibodies?

High background signal can obscure specific DHFR detection, requiring specialized troubleshooting approaches:

More stringent blocking conditions can reduce non-specific binding. Try increasing blocking reagent concentration (e.g., from 5% to 10% BSA or non-fat dry milk), extending blocking time to 2 hours at room temperature, or testing alternative blocking agents such as normal serum from the same species as the secondary antibody.

For Western blots, increasing the number and duration of washing steps can significantly reduce background. Implement at least 5 washes of 10 minutes each with TBST containing 0.1-0.3% Tween-20, using gentle agitation.

If using a polyclonal DHFR antibody that exhibits high background, consider pre-adsorption against tissue or cell lysates from species of interest to remove non-specific antibodies. Alternatively, switching to a monoclonal DHFR antibody might provide higher specificity at the expense of potentially lower sensitivity .

For IHC applications, endogenous peroxidase blocking should be optimized. Use 3% hydrogen peroxide in methanol for 15-30 minutes, followed by thorough washing. Additionally, when using avidin-biotin detection systems, endogenous biotin blocking may be necessary, particularly in biotin-rich tissues like liver and kidney.

Secondary antibody concentration should be carefully titrated, as excessive secondary antibody is a common source of background. Try more dilute secondary antibody concentrations (e.g., 1:10000 instead of 1:5000) while extending incubation time to maintain sensitivity.

What approaches can validate the specificity of observed DHFR antibody staining patterns?

Confirming the specificity of DHFR antibody staining requires multiple validation strategies:

Peptide competition assays provide strong evidence for antibody specificity. Pre-incubating the DHFR antibody with excess purified recombinant DHFR protein or immunizing peptide should abolish or significantly reduce specific staining in all applications.

Correlating staining patterns across multiple techniques strengthens confidence in specificity. If a DHFR antibody yields consistent results across Western blot, IHC, and IF applications, this supports genuine target recognition. The search results indicate that several DHFR antibodies have been validated across multiple applications .

Genetic approaches represent the gold standard for antibody validation. Using DHFR knockout or knockdown models (via CRISPR-Cas9 or siRNA) provides definitive evidence of specificity when staining is absent or significantly reduced in these samples compared to wild-type controls. Several DHFR antibodies have been validated using KD/KO approaches, as referenced in publications .

Multiple antibody concordance offers additional validation. Using two or more antibodies targeting different epitopes of DHFR that produce similar staining patterns strongly supports specificity. The search results describe DHFR antibodies targeting various regions, including AA 1-50, AA 2-187, and AA 135-164 .

For immunofluorescence applications, co-localization with proteins known to interact with DHFR or share its subcellular distribution can provide further validation. This approach is particularly valuable when combined with high-resolution microscopy techniques such as confocal or super-resolution microscopy.

How should DHFR antibody performance be validated in gene amplification studies?

Validating DHFR antibody performance in gene amplification studies requires specialized approaches:

When working with DHFR/MTX-mediated gene amplification systems, antibody performance should be validated by demonstrating a correlation between MTX concentration steps and DHFR protein levels. Western blot analysis using carefully calibrated protein loading and quantitative detection methods can establish this relationship .

Specificity validation in gene amplification contexts should include comparison between parental dhfr-deficient cell lines (e.g., dhfr-knockout HEK293 cells) and amplified clones . The parental line should show minimal or no DHFR signal, while amplified clones should display concentration-dependent increases in DHFR expression corresponding to MTX selection levels.

Functional validation can be performed by assessing DHFR enzyme activity in parallel with antibody-based detection. Enzymatic assays measuring the conversion of dihydrofolate to tetrahydrofolate can confirm that the protein detected by the antibody possesses catalytic activity consistent with DHFR.

For long-term stability studies of gene amplification, DHFR antibodies can be used to monitor expression levels over time both in the presence and absence of selection pressure. Research has shown that some high-producing clones maintain elevated DHFR expression during long-term culture (3 months) even without selection pressure, while others show significant decreases in expression .

Immunofluorescence combined with fluorescence in situ hybridization (FISH) can provide correlative evidence linking DHFR protein expression with gene copy number amplification. This approach can visualize both the amplified gene loci and the resulting protein expression within the same cells.

How are DHFR antibodies being utilized in developing novel therapeutic approaches?

DHFR antibodies contribute to innovative therapeutic development through multiple research applications:

In targeted drug delivery research, DHFR antibodies can help validate novel antifolate drug conjugates by confirming their specific binding to DHFR-expressing cells. Immunofluorescence and flow cytometry applications using DHFR antibodies can assess whether drug conjugates co-localize with their intended target in cellular models.

For cancer immunotherapy approaches targeting DHFR-overexpressing tumors, DHFR antibodies are essential for patient stratification studies. Immunohistochemical analysis of tumor biopsies using validated DHFR antibodies (dilution range 1:50-1:500) can identify patients with DHFR-overexpressing tumors who might benefit from such targeted therapies.

DHFR-targeting PROTAC (Proteolysis Targeting Chimeras) development requires confirmation of target engagement and degradation. Western blot analysis using DHFR antibodies provides direct evidence of DHFR degradation following PROTAC treatment, while immunofluorescence can visualize changes in subcellular localization during the degradation process.

In developing resistance-overcoming therapeutic strategies, DHFR antibodies help characterize resistance mechanisms in patient-derived xenograft models or clinical samples. Immunohistochemistry and Western blot applications can reveal whether resistance correlates with DHFR mutations, overexpression, or alterations in post-translational modifications.

What are the considerations for using DHFR antibodies in multiplexed imaging applications?

Multiplexed imaging with DHFR antibodies requires specialized optimization:

When designing multiplexed immunofluorescence panels including DHFR antibodies, careful selection of complementary antibodies is essential. Primary antibodies should ideally originate from different host species to prevent cross-reactivity between secondary antibodies. If using multiple rabbit-derived antibodies including DHFR antibodies , sequential staining with complete stripping or direct conjugation of primary antibodies may be necessary.

Spectral considerations are crucial for fluorophore selection in multiplexed imaging. Choose fluorophores with minimal spectral overlap, and when using DHFR antibodies in combination with other markers, ensure appropriate compensation controls are included to correct for any bleed-through between channels.

For tissue-based multiplexed imaging, antigen retrieval conditions must be compatible with all target antigens. Since DHFR antibodies typically require TE buffer at pH 9.0 or citrate buffer at pH 6.0 for optimal retrieval , other antibodies in the panel should be tested under these conditions to ensure compatibility.

Signal amplification strategies may be necessary when combining antibodies with vastly different expression levels. If DHFR expression is relatively low compared to other targets in the multiplexed panel, tyramide signal amplification or other amplification methods may be required specifically for the DHFR channel.

Validation of multiplexed panels should include single-stain controls for each antibody to confirm that the staining pattern in multiplexed format matches that observed in single-stain experiments. This is particularly important for DHFR antibodies, which should maintain their characteristic staining pattern regardless of the presence of other antibodies.

Human expert: This comprehensive FAQ collection addresses both fundamental aspects of DHFR antibodies and advanced research applications while providing methodological guidance for researchers across various experimental contexts.